Chronic NMDA administration to rats increases brain pro-apoptotic factors while decreasing anti-Apoptotic factors and causes cell death
Hyung-Wook Kim, Yunyoung C Chang, Mei Chen, Stanley I Rapoport and Jagadeesh S Rao*

Address: Brain Physiology and Metabolism Section, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA
Email: Hyung-Wook Kim - kimhyung@mail.nih.gov; Yunyoung C Chang - yunyoung.chang@gmail.com; Mei Chen - chenmei@mail.nih.gov; Stanley I Rapoport - sir@helix.nih.gov; Jagadeesh S Rao* - jrao@mail.nih.gov
* Corresponding author

Abstract

Background: Chronic N-Methyl-d-aspartate (NMDA) administration to rats is reported to increase arachidonic acid signaling and upregulate neuroinflammatory markers in rat brain. These changes may damage brain cells. In this study, we determined if chronic NMDA administration (25 mg/kg i.p., 21 days) to rats would alter expression of pro- and anti-apoptotic factors in frontal cortex, compared with vehicle control.

Results: Using real time RT-PCR and Western blotting, chronic NMDA administration was shown to decrease mRNA and protein levels of anti-apoptotic markers Bcl-2 and BDNF, and of their transcription factor phospho-CREB in the cortex. Expression of pro-apoptotic Bax, Bad, and 14-3-3ζ was increased, as well as Fluoro-Jade B (FJB) staining, a marker of neuronal loss.

Conclusion: This alteration in the balance between pro- and anti-apoptotic factors by chronic NMDA receptor activation in this animal model may contribute to neuronal loss, and further suggests that the model can be used to examine multiple processes involved in excitotoxicity.

Background

Glutamate is the major excitatory neurotransmitter in vertebrate brain. Glutamate acts on two different classes of receptors, ionotropic glutamatergic receptors and G-protein-coupled metabotropic receptors. The ionotropic receptors are further classified into α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), kainate, and N-methyl-D-aspartate (NMDA) receptors [1]. Binding of glutamate to NMDA receptors (NMDAR) results in an influx of extracellular Ca2+ into the cell, which leads to the activation of many Ca2+-dependent enzymes such as calpain [2], calcineurin [3], inducible nitric oxide synthase (iNOS) expression [4] and arachidonic acid (AA, 20:4n-6) selective cytosolic phospholipase A2 (cPLA2)[5,6]. NMDAR are present throughout the brain and predominantly in frontal cortex and hippocampal CA1 region [7]. Activation of NMDAR also induces signaling cascades involved in learning and memory, synaptic excitability and plasticity, and neuronal degeneration [8]. Overactivation of glutamate receptors can result in the death of neurons through a process termed excitotoxicity. Excitotoxicity has been implicated in several neurodegenerative diseases, including Alzheimer disease [9-11], Huntington disease [12], schizophrenia [13], and bipolar...
disorder [14-16]. Chronic NMDA administration to rats reduced NMDAR subunits and increased arachidonic acid cascade markers in rat frontal cortex [6]. Similarly, an altered NMDAR subunits [17,18] and increased arachidonic acid cascade markers have been reported in Alzheimers patients[19,20].

Glutamate was reported to trigger DNA degradation, apoptotic cell death, and increase the Bcl-2-associated X protein (Bax) to B-cell lymphoma (Bcl)-2 ratio in cells in vitro [21-24]. In addition, AA was reported to induce apoptosis in vitro by producing mitochondrial damage [25], activating caspasas-3 and -9, releasing cytochrome C [26], decreasing expression of brain-derived neurotrophic factor (BDNF) [27], and reducing neuronal viability [28]. Dietary deprivation of n-3 polyunsaturated fatty acids (n-3 PUFAs) in rats increased AA signaling while decreasing BDNF expression in frontal cortex [29,30]. In contrast, chronic administration of mood stabilizers to rats decreased brain expression of cPLA2, as well as AA turnover in brain phospholipids [31]. Mood stabilizers also increased expression of anti-apoptotic Bcl-2 and BDNF in the rat frontal cortex [32-34].

We have established an animal model of excessive NMDA signaling in rats by administering a subconvulsive dose of NMDA for 21 days. This model demonstrates upregulated markers of brain AA metabolism, including increased turnover of AA in brain phospholipids and increased expression of AA-selective cPLA2 and the cPLA2 gene transcription factor, activator protein (AP)-2 [6,35]. It also demonstrates increased brain neuroinflammatory markers, consistent with crosstalk between NMDAR-mediated excitotoxicity and neuroinflammation [4].

In our present study, we wished to see if chronic NMDA administration to rats, as a model of excitotoxicity, also would alter the balance of pro- and anti-apoptotic factors in brain and lead to neuronal death. To the extent that this model represents clinical excitotoxicity, it might be used for drug development and for understanding interactions among different brain processes that lead to cell death. We studied the frontal cortex because we had studied this region previously in this model [4,6].

Methods

Animals

The study was conducted following the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals (Publication no. 80-23) and was approved by the Animal Care and Use Committee of the "Eunice Kennedy Shriver" National Institute of Child Health and Human Development. Male CDF-344 rats weighing 200-215 g (Charles River Laboratories; Wilmington, MA, USA) were randomly assigned to a control group (n = 10) that received vehicle (0.9% saline i.p.) once daily for 21 days, or to an NMDA group (n = 10) that received 25 mg/kg i.p. NMDA (Sigma Chemical Co., St Louis, MO, USA) once daily for 21 days. This dose does not produce convulsions but can cause paroxysmal EEG activity [36] and an increase in brain AA metabolism in rats [37]. Three hours after the last saline or NMDA injection, rats were anesthetized with CO2 and then decapitated. The brain was rapidly excised and the frontal cortex dissected, frozen in 2-methylbutane at -50°C, and stored at -80°C until use.

Preparation of Cytosolic Fractions

Cytosolic fractions were prepared from frontal cortex as previously described [6]. Tissue from control or chronic NMDA rats was homogenized with a Polytron homogenizer in a buffer consisting of 20 mM Tris-HCl (pH 7.4), 2 mM EGTA, 5 mM EDTA, 1.5 mM pepstatin, 2 mM leupeptin, 0.5 mM phenylmethylsulfonyl fluoride, 0.2 U/ml aprotinin, and 2 mM dithiothreitol. The suspension was centrifuged at 100,000 × g for 60 min at 4°C. The resulting supernatant was the cytosolic fraction. Protein concentrations of cytosolic fractions were determined by using a protein reagent (Bio-Rad, Hercules, CA).

The frontal cortex nuclear fraction was prepared from the control and NMDA administered rats as previously described [6].

Western Blot Analysis

Proteins from cytosolic extracts (65 μg) were separated on 10-20% SDS-polyacrylamide gels (PAGE) (Bio-Rad), and then were electrophoretically transferred to a nitrocellulose membrane (Bio-Rad). Cytosolic blots were incubated with primary antibodies for BDNF, Bcl-2, Bcl-2-associated X protein (Bax), Bcl-2-associated death promoter (Bax), Bcl-2-associated death promoter (Bad), and 14-3-3z (1: 1000) (Santa Cruz Biotech, Santa Cruz, CA). The blots then were incubated with appropriate HRP-conjugated secondary antibodies (Bio-Rad) and were visualized using a chemiluminescence reaction (Amersham, Piscataway, NJ) on X-ray film (XAR-5, Kodak, Rochester, NY). Optical densities of immunoblot bands were measured using Alpha Innotech Software (Alpha Innotech, San Leandro, CA) and were normalized to β-actin (Sigma) to correct for unequal loading. All experiments were carried out twice with up to 6 independent samples.

BDNF and phospho-CREB Protein Levels

BDNF and phospho-cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) levels were measured in brain cytosolic and nuclear extracts using an ELISA kit according to the manufacturer's instructions (Chemicon International, Temecula, CA). BDNF levels are expressed in pmol/mg protein and phospho-CREB levels were expressed as percent of control.
Total RNA Isolation and RT-PCR
Total RNA was isolated from frontal cortex of control and chronic NMDA-administered rats using an RNeasy lipid tissue mini kit (Qiagen, Valencia, CA, USA). Expression of BDNF, Bcl-2, Bax, and Bad was determined using specific primers and probes purchased from TaqMan® gene expression assays (Applied Biosystems). Data were expressed as the level of the target gene mRNA in brain from NMDA-administered animals normalized to the level of the endogenous control mRNA (β-globulin), and relative to values in brains from control saline-injected rats (calibrator) [38]. All experiments were carried out in duplicate with six independent samples per group.

FJB staining
Brains from control and NMDA administered rats (frontal cortex) were sectioned coronally (25 μm) on a cryostat (Bright Instrument Company, Ltd., Huntingdon, England) and then mounted on gelatin-coated glass specimen slides. Staining with FJB (Histo-Chem, Jefferson, AR) was performed as described [39]. Briefly, the tissue slides were dehydrated in 70% ethanol and then hydrated with distilled water. After hydration, they were immersed in FJB stain for 20 min at room temperature, washed with distilled water and dried at 50°C for 10 min. The slides were mounted with the cover slip with DPX and examined under a fluorescence microscope.

Statistical Analysis
Data are expressed as means ± SEM. Statistical significance was calculated using two-tailed, unpaired t-test, with significance set at p < 0.05.

Results
Decreased levels of anti-apoptotic factors
Chronic NMDA administration for 21 days, compared with chronic saline, significantly decreased protein levels of BDNF (75%; p < 0.001) (Figure 1A). Bcl-2 (33%; p <
0.05) (Figure 1B), and phospho-CREB (39%; p < 0.001) (Figure 1C) in rat frontal cortex. The decreases in these protein levels were associated with decreases in their mRNA levels. Thus, chronic NMDA significantly decreased mRNA levels of BDNF (0.6 fold; p < 0.01) (Figure 1D) and of Bcl-2 (0.6 fold; p < 0.01) (Figure 1E).

Increased levels of pro-apoptotic factors

In contrast to the reductions in anti-apoptotic factors, chronic NMDA increased protein levels of pro-apoptotic Bad (71%; p < 0.05) (Figure 2A) and Bax (30%; p < 0.01) (Figure 2B). mRNA levels also were increased for both Bad (1.4 fold; p < 0.05) (Figure 2C) and Bax (0.23 fold; p < 0.05) (Figure 2D) by chronic NMDA. Chronic NMDA administration increased the protein level of 14-3-3ζ (50%; p < 0.05) (Figure 3A).

Evidence of cell death

Chronic NMDA administration increased FJB staining, a marker of neuronal loss, in rat frontal cortex (Figure 3B).

Discussion

Chronic daily administration of a non-convulsive dose of NMDA to adult male rats significantly decreased frontal cortex protein and mRNA levels of the anti-apoptotic factors BDNF and Bcl-2, and of their transcription factor, phospho-CREB. In contrast, chronic NMDA significantly increased frontal cortex protein and mRNA levels of Bad
and Bax and of the protein level of 14-3-3ζ, pro-apoptotic factors, as well as Fluoro Jade-B staining, a marker of neuronal death, in rat frontal cortex. These data can be added to evidence that chronic NMDA under the same administration paradigm increased frontal cortex expression of inflammatory markers (protein and mRNA levels of interleukin-1 beta, tumor necrosis factor alpha, glial fibrillary acidic protein and inducible nitric oxide synthase) [4], decreased frontal cortex NMDAR (NR)-1 and NR-3A subunits, and increased activity, phosphorylation, protein, and mRNA levels of cPLA2, but did not change activity or protein levels of secretory sPLA2 or calcium-independent iPLA2 [6]. Chronic NMDA also increased the DNA-binding activity of AP-2 and its protein levels of AP-2 alpha and beta subunits [6], which are recognized on the promoter region of cPLA2 gene [40] as well as turnover and other kinetic markers of AA metabolism in frontal cortex of rat brain [35]. These changes did not follow administration of a single 25 mg/kg i.p. dose of NMDA and thus were a consequence of long term activation of NMDARs [6]. Together, they provide a profile of an experimental and probably evolving animal model of excitotoxicity, which might be exploited for future drug development and for understanding interactions of processes of excitotoxicity. There is evidence that excitotoxicity plays a role in a number of neuropsychiatric and neurodegenerative disorders, including Alzheimer disease [9-11], Huntington’s disease [12], schizophrenia [13], and bipolar disorder [14,16,41].

The effects of chronic NMDA in rats suggest alterations of multiple signaling cascades such as calpain [2], calcineurin [3] and iNOS expression [4] but it may be premature to ascribe a change in one to a change in another. Nevertheless, increased AA metabolism caused by chronic NMDA may be involved in altering the balance between pro- and anti-apoptotic factors, leading in turn to the observed neuronal loss. Increased AA exposure decreased
BDNF protein in spinal cord neurons in vitro [27], induced mitochondrial damage [25], activated caspases-3 and -9, released cytochrome C from mitochondria [26] and decreased neuronal viability [28].

Expression of BDNF and Bcl-2 is regulated mainly by CREB [42]. BDNF and Bcl-2 play important roles in cell survival and plasticity, and in growth and differentiation of new neurons and synapses [43]. Increased AA signaling may interfere with transcription of neuronal survival factors [27,44-47]. Downregulation of BDNF and Bcl-2 could occur through a decrease in their transcription factor phospho-CREB [48], as was found in this study. BDNF also may regulate Bcl-2 levels through activation of the MAP kinase cascade and the downstream phosphorylation of CREB protein [49].

Bcl-2 can be repressed by the AP-2 transcription factor [50], resulting in apoptosis. Chronic NMDA in rats increased the DNA-binding activity of AP-2 and protein levels of its alpha and beta subunits [51]. AP-2 also is a transcription factor of the cPLA2 gene, and its overexpression may lead to upregulated cPLA2 activity and of AA signaling upon chronic NMDA administration [51]. Thus, increased AP-2 binding activity or decreased BDNF caused by chronic NMDA may have led to the decreased Bcl-2 expression in the present study.

Consistent with the notion that increased AA signaling reduces BDNF expression, rats deprived of dietary essential n-3 PUFAs for 15 weeks demonstrated increased brain AA signaling and reduced mRNA and protein levels of phospho-CREB and BDNF [29,30]. In relation to this, chronic NMDA administration also increased brain cPLA2 activity, phosphorylation, protein, and mRNA levels, as well as AA turnover in brain phospholipids [6,35].

14-3-3ζ proteins bind the pro-apoptotic protein Bad [52]. Disassociation of 14-3-3ζ from Bad causes dephosphorylation of Bad by protein phosphatase 2A [53], allowing Bad to move from the cytoplasm to mitochondria, where it can displace Bax from Bcl-xL [54] and promote apoptosis. There also may be a more direct mechanism by which AA induces polymerization of 14-3-3ζ and dissociation from Bad [55]. The combination of increased expression of 14-3-3ζ and increased AA signaling [6] caused by chronic NMDA may have contributed to the neuronal loss, which is suggested by the increased FJB staining. Studies also have reported increased protein levels of 14-3-3ζ associated with neurodegenerative disease [56-58]. Increased 14-3-3ζ protein levels caused by chronic NMDA may be a secondary response to the observed increased Bad expression or be due to the increased AA signalling. Further studies are needed to understand the direct role of 14-3-3ζ in NMDA mediated apotosis.

Conclusion
Chronic NMDA excitotoxicity may be involved in the apoptosis in neurodegenerative diseases, while targeting the excitotoxicity with drugs may be a useful therapeutic approach in these neurodegenerative diseases by way of reducing apoptosis in brain.

Abbreviations
AP-2: activator protein-2; BDNF: brain derived neurotrophic factor; Bcl-2: B-cell lymphoma-2; CREB: cAMP response element binding protein; phospho-CREB: phosphorylated CREB; Bax: Bcl-2-associated X protein; Bad: Bcl-2-associated death promoter; Fluoro-Jade B: FJB.

Authors' contributions
HWK and YCC were carried out the experiments and analysis. SIR and JSR were involved in designing and writing, editing the manuscript.

Acknowledgements
This work was entirely supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. We thank Dr Sang-Ho Choi for assistance with florescence microscopy. We thank Kathy Benjamin for critically reading the manuscript.

References
1. Nakamitsu S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992, 258(5082):597-603.
2. Siman R, Noszek JC: Excitatory amino acids activate calpain I and induce structural protein breakdown in vivo. Neuron 1988, 1(4):279-287.
3. Xifro X, Garcia-Martinez JM, Del Toro D, Ablerch J, Perez-Navarro E: Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. J Neurochem 2008, 105(5):1596-1612.
4. Chang YC, Kim HW, Rapoport SI, Rao JS: Chronic NMDA administration increases neuroinflammatory markers in rat frontal cortex: cross-talk between excitotoxicity and neuroinflammation. Neurochem Res 2008, 33(11):2318-2323.
5. Weichol E, Hilgert M, Chatterjee SS, Lehr M, Klein J: Bilobalide, a constituent of Ginkgo bioloa, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1999, 360(6):609-615.
6. Rao JS, Ertley RN, Rapoport SI, Bazinet RP, Lee HJ: Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2. J Neurochem 2007, 102(6):1918-1927.
7. Monahan DT, Cotman CW: Distribution of N-methyl-D-aspartate-sensitive L-[3H]glutamate-binding sites in rat brain. J Neurosci 1985, 5(11):2909-2919.
8. Tilleux S, Hermans E: Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007, 85(10):2059-2070.
9. Fang M, Li J, Tiu SC, Zhang L, Wang M, Yew DT: N-methyl-D-aspartate receptor and apoptosis in Alzheimer's disease and multifactor dementia. J Neurosci Res 2005, 81(2):269-274.
10. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gours GD, et al.: Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005, 8(8):1051-1058.
11. Hallert PJ, Dunah AW, Ravenscroft P, Zhou S, Bezd E, Crossman AR, Brodie JM, Standaert DG: Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005, 48(4):503-516.
Chang YC, Kim HW, Rapoport SI, Rao JS. Chronic NMDA administration increases neuroinflammatory markers in rat frontal cortex: correlation between excitotoxicity and neuroinflammation. Neurochem Res 2008, 33(11):2318-2323.

Chuang DM: The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann NY Acad Sci 2005, 1053(5):195-204.

Chung HK, Moore GJ, Rajkowitsch L, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000, 5(6):578-593.

Lee HJ, Rao JS, Chang L, Rapoport SI. Chronic N-methyl-D-aspartate administration increases the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat. J Lipid Res 2008, 49(1):162-168.

Ormandy GC, Song L, Jope RS: Analysis of the convulsant-potentiating effects of lithium in rats. Exp Neurol 1991, 111(3):336-361.

Ahn YH, Shin SY, Lee DH, Jeong YM, Lee YS, Park YK, at al. Reduction of NR1 and NR2A subunit isoforms in Alzheimer's disease. BMC Neurosci 2007, 8(8):94-93.

Chen TC, Sung Y, Fujita S, et al. Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamic Nucleus Centromedian and Superior Thalamic Nucleus in Patients with Huntington's Disease. J Neurochem 2004, 90(4):1255-1262.

Chen TC, Sung Y, Fujita S, et al. Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamic Nucleus Centromedian and Superior Thalamic Nucleus in Patients with Huntington's Disease. J Neurochem 2004, 90(4):1255-1262.

Chen TC, Sung Y, Fujita S, et al. Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamic Nucleus Centromedian and Superior Thalamic Nucleus in Patients with Huntington's Disease. J Neurochem 2004, 90(4):1255-1262.
54. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 1996, 87(4):619-628.

55. Brock TG: Arachidonic acid binds 14-3-3zeta, releases 14-3-3zeta from phosphorylated BAD and induces aggregation of 14-3-3zeta. Neurochem Res 2008, 33(5):801-807.

56. Umahara T, Uchihi T, Tsuchiya K, Nakamura A, Ikeda K, Iwamoto T, Takasaki M: Immunolocalization of 14-3-3 isoforms in brains with Pick body disease. Neurosci Lett 2004, 371(2-3):215-219.

57. Umahara T, Uchihi T, Tsuchiya K, Nakamura A, Iwamoto T, Ikeda K, Takasaki M: 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease. Acta Neuropathol 2004, 108(4):279-286.

58. Wiltfang J, Otto M, Baxter HC, Bodemer M, Steinacker P, Bahn E, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, et al.: Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurochem 1999, 73(6):2485-2490.